Esperion Therapeutics | ESPR - Selling And Administration Expenses

Stock Price
3.49
Daily Change
0.10 2.80%
Monthly
-1.83%
Yearly
85.37%
Q1 Forecast
2.70

Esperion Therapeutics reported $39.98M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Alnylam Pharmaceuticals USD 262.59M 60.72M Sep/2025
Alterity Therapeutics Limited AUD 2.29M 649.1K Jun/2023
Amarin USD 17.94M 17.86M Sep/2025
Amgen USD 1.94B 237M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Cipla INR 13.25B 101.8M Dec/2025
CSL USD 727M 453M Jun/2025
Cytokinetics USD 158.75M 93.03M Sep/2025
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
Geron USD 39M 437K Sep/2025
Grifols EUR 333.1M 157M Sep/2025
Halozyme Therapeutics USD 37.53M 4.53M Sep/2025
Heron Therapeutics USD 23.34M 4.18M Sep/2024
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
Merck USD 2.85B 215M Dec/2025
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Moderna USD 268M 38M Sep/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 84.05M 1.22M Sep/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
United Therapeutics USD 152M 60.5M Sep/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024